Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-05-20, Stock:PFE, The news for the past five days is as follows:
2020-05-13: NEWS1: Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day.NEWS2: Drug Sector Highly Resilient Amid Coronavirus Mayhem: 5 Picks.NEWS3: Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners.NEWS4: Pfizer Plans To Test Covid-19 Vaccine On Thousands Of Patients By September- Report.NEWS5: Pfizer Plans To Test Coronavirus Vaccine On Thousands Of Patients By September.
2020-05-14: NEWS1: The Zacks Analyst Blog Highlights: LLY, AZN, PFE, SNY and BMY.NEWS2: Coronavirus Vaccine Progress Accelerates.NEWS3: Three Dividend Growth Stocks We Recently Purchased for Our Portfolio.NEWS4: Relaxing the Lockdown: Move Slowly, Stay Nimble.NEWS5: Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age.
2020-05-15: NEWS1: Why Sarepta Has A Leg Up On Pfizer With A Rival Gene Therapy: Analysts.NEWS2: Pfizer Posts Positive Data from Duchenne Muscular Dystrophy Candidate, but Still Trails Rival Sarepta Therapeutics.NEWS3: Trump unveils vaccine effort, says country will be back on its feet with or without one.NEWS4: Sarepta Gains After Pfizer DMD Gene Therapy Data Fall Short.NEWS5: Can Pfizer Undercut Sarepta Therapeutics With A Rival Gene Therapy?.NEWS6: Pfizer to launch late stage DMD gene therapy trial despite hospitalizations.NEWS7: Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study.
2020-05-18: NEWS1: We anticipate a U-Shaped to Swoosh-Shaped recovery: Strategist.NEWS2: Moderna COVID-19 vaccine data is ‘baby-step’ in right direction: Expert.NEWS3: Here’s what it will take for the stock market to hit a new record within 2 months.NEWS4: Moderna Soars: Biotech ETFs in Focus.NEWS5: Pfizer Inc. -- Moody's assigns A1 to Pfizer's notes; on review for downgrade.NEWS6: Sarepta Surges on Rival Pfizer's DMD Gene Therapy Study Data.NEWS7: Who Is Winning the COVID-19 Vaccine Race?.NEWS8: Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy.NEWS9: Pfizer Just Began A Coronavirus Vaccine Test — Is PFE Stock A Buy?.NEWS10: Glaxo-held firm ends HIV study early as injectable shows higher efficacy than daily pill.
2020-05-19: NEWS1: Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example'.NEWS2: GlaxoSmithKline, Pfizer, and Shionogi's HIV Prevention Candidate Outperforms Gilead's Truvada.NEWS3: Glaxo's Long-Acting HIV Injection Effective Than Daily Pills.NEWS4: A Covid-19 Vaccine Could Be Worth Billions for Moderna and Its Rivals.NEWS5: Pfizer Seeks To Raise $4 Billion From Debt Sale.NEWS6: What's Behind Axsome Therapeutics' Miracle Pipeline?.NEWS7: What's Behind Axsome Therapeutics' Miracle Pipeline?.NEWS8: Market pros have high hopes for a COVID-19 vaccine: Morning Brief.NEWS9: Pfizer Prices $4,000,000,000 Debt Offering.

Answer: Decrease